AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.

AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie Inc. (NYSE:ABBV) is well-positioned to deliver a top-tier long-term outlook, driven by Humira’s success and strategic ...

AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Maggie Smith, acting legend of 'Harry Potter' and 'Downton Abbey' fame, dies at 89 Aerial footage shows extensive Helene ...

Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...